Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

This article was originally published on Nasdaq

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has granted marketing authorization to its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or st

Responses